Valion Bio (VBIO)

• Market cap: $1.29M
• 1 day: 11.51%
• 5 days: 7.45%
• 1 month: -40.37%
• 3 months: -68.36%
• 6 months: -71.82%
• Year to date: -78.17%
• 1 year: -91.01%
• 5 years: -100%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.

Employees: 52